Skip to content

Asset turnover at other companies

Incyte logo
IncyteINCY
0.8×+0.1×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-0.1×
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
0.0×
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
0.0×
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
0.2×-0.9×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
0.6×+0.3×

Other financials

Income statement

See full
Revenue$2.0M+37.2%
Gross profit$1.6M+68.7%
Operating income-$22.2M-22.7%
Net income-$19.8M-31.4%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$28.7M-5.6%
Total debt$2.0M-20.1%
Total equity$143.6M-0.3%
Total assets$198.7M+0.3%

Cash flow

See full
Operating cash flow-$18.1M-39.0%
CapEx$13.0K-69.8%
Free cash flow-$18.2M-38.6%

Valuation

See full
Market cap$685.75M+337%
Enterprise value$659.07M+410%
P/S82×+73.1×

Profitability

See full
Gross margin76.3%-9.7pp
Operating margin-961.9%+259pp
Net margin-832.6%+132pp
FCF margin-624.9%

Returns & leverage

See full
Return on equity-48.4%-15.4pp
Debt / equity0.0×
Current ratio-1.0×

Where this comes from

Calculated from Aclaris Therapeutics’s reported figures.

Based on trailing twelve months.

The official record: Aclaris Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Aclaris Therapeutics's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Aclaris Therapeutics's asset turnover?
Aclaris Therapeutics (ACRS) reported asset turnover of 0× in Q1 2026.
How has Aclaris Therapeutics's asset turnover changed year-over-year?
Aclaris Therapeutics's asset turnover decreased by 55.8% year-over-year, from 0.1× to 0×.
What is the long-term trend for Aclaris Therapeutics's asset turnover?
Over 5 years (2020 to 2025), Aclaris Therapeutics's asset turnover has grown at a -11.7% compound annual growth rate (CAGR), from 0.1× to 0×.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.